Drawing for XEMPLAR

USPTO serial 76578674

XEMPLAR

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
LE, KHANH M
Law office
TTAB

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 604: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with XEMPLAR?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Kimberly B. Herman

Richard B. Verner Sullivan & Worcester LLP1290 Avenue of the AmericasNew York, NY 10104UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
010Pharmaceutical drug delivery devices, namely pharmaceutical aerosol devices for medical useABANDONED—
042Pharmaceutical drug development services in relation to the following diseases-- asthma, chronic obstructive pulmonary disease, lung cancer, lung infections, pulmonary arterial hypertension, arrhythmias and pain management for the foregoing; pharmaceutical research services, namely, analytical and in vitro method development, formulation development and validation services in relation to the following diseases-- asthma, chronic obstructive pulmonary disease, lung cancer, lung infections, pulmonary arterial hypertension, arrhythmias and pain management for the foregoing; pharmaceutical drug testing services in relation to the following diseases-- asthma, chronic obstructive pulmonary disease, lung cancer, lung infections, pulmonary arterial hypertension, arrhythmias and pain management for the foregoingABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 5, 2008MAB4ABANDONMENT NOTICE MAILED - INTER PARTES DECISION—
Aug 5, 2008ABN4ABANDONMENT - AFTER INTER PARTES DECISION—
Aug 5, 2008OP.TOPPOSITION TERMINATED NO. 999999—
Aug 5, 2008OP.DOPPOSITION DISMISSED NO. 999999—
Mar 13, 2006OP.IOPPOSITION INSTITUTED NO. 999999—
Oct 24, 2005ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Sep 27, 2005PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 7, 2005NPUBNOTICE OF PUBLICATION—
Aug 16, 2005PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Aug 15, 2005ALIEASSIGNED TO LIE—
Aug 8, 2005CNEAEXAMINERS AMENDMENT MAILED—
Aug 5, 2005CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 5, 2005CNEAEXAMINERS AMENDMENT -WRITTEN—
Jul 14, 2005ACECAMENDMENT FROM APPLICANT ENTERED—
Jun 27, 2005CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 27, 2005MAILPAPER RECEIVED—
Apr 25, 2005CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 23, 2005CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 1, 2005ACECAMENDMENT FROM APPLICANT ENTERED—
Mar 21, 2005CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 21, 2005MAILPAPER RECEIVED—
Feb 25, 2005CNFRFINAL REFUSAL MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Feb 24, 2005CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Feb 3, 2005ACECAMENDMENT FROM APPLICANT ENTERED—
Jan 19, 2005CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 19, 2005MAILPAPER RECEIVED—
Sep 30, 2004CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 29, 2004CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 17, 2004DOCKASSIGNED TO EXAMINER—
Mar 16, 2004NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance